Yuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., . . . Gnjatic, S. (2011). Integrated NY-ESO-1 antibody and CD8(+) T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. National Academy of Sciences.
Chicago-стиль цитированияYuan, Jianda, et al. Integrated NY-ESO-1 Antibody and CD8(+) T-cell Responses Correlate With Clinical Benefit in Advanced Melanoma Patients Treated With Ipilimumab. National Academy of Sciences, 2011.
MLA-цитированиеYuan, Jianda, et al. Integrated NY-ESO-1 Antibody and CD8(+) T-cell Responses Correlate With Clinical Benefit in Advanced Melanoma Patients Treated With Ipilimumab. National Academy of Sciences, 2011.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.